The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo, AstraZeneca’s Symbicort, Merck’s Dulera [off-label in COPD]), and LABA/LAMAs (e.g., GlaxoSmithKline’s Anoro, Boehringer Ingelheim’s Stiolto, AstraZeneca’s Bevespi, Sunovion’s Utibron) compete for a share of the maintenance market. Likewise, several short-acting inhaled therapies contend for a share of the acute COPD market, (e.g., Teva’s ProAir, GlaxoSmithKline’s Ventolin, Boehringer Ingelheim’s Combivent). The market is expected to become even more competitive in the next several years, given the recent and upcoming approvals of triple LABA/LAMA/ICS combinations (e.g., GlaxoSmithKline’s Trelegy), the recent and upcoming approvals of additional nebulized LAMAs, and the potential launch of the first COPD biologics, making brand differentiation and understanding of key patient characteristics even more critical for marketers.
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive real-world data (RWD) repository.
Markets covered: United States
Real World Data: U.S. electronic health records and claims data.
Key drugs covered: Spiriva, Tudorza, Incruse, Brovana, Advair, Symbicort, Dulera, Breo, Anoro, Stiolto, Utibron, Bevespi, Combivent, ProAir, Ventolin
Key analysis provided: